Equities analysts expect STAAR Surgical (NASDAQ:STAA) to announce $0.03 earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Zero analysts have provided estimates for STAAR Surgical’s earnings. STAAR Surgical posted earnings of $0.02 per share during the same quarter last year, which indicates a positive year over year growth rate of 50%. The business is expected to announce its next earnings report on Thursday, March 1st.

According to Zacks, analysts expect that STAAR Surgical will report full-year earnings of $0.02 per share for the current year. For the next year, analysts anticipate that the business will report earnings of $0.19 per share. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research analysts that cover STAAR Surgical.

Several equities research analysts recently commented on the stock. Canaccord Genuity boosted their price objective on shares of STAAR Surgical from $17.50 to $20.00 and gave the company a “buy” rating in a research report on Friday, November 17th. BidaskClub cut shares of STAAR Surgical from a “sell” rating to a “strong sell” rating in a research report on Saturday, January 6th. Finally, Benchmark reaffirmed a “buy” rating and issued a $21.00 price objective on shares of STAAR Surgical in a research report on Monday, November 20th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and two have assigned a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus target price of $17.67.

In other STAAR Surgical news, VP Keith Holliday sold 6,000 shares of STAAR Surgical stock in a transaction on Tuesday, November 21st. The shares were sold at an average price of $16.65, for a total value of $99,900.00. Following the sale, the vice president now directly owns 45,969 shares in the company, valued at approximately $765,383.85. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 3.40% of the stock is currently owned by insiders.

A number of hedge funds have recently modified their holdings of the business. Renaissance Technologies LLC increased its stake in STAAR Surgical by 18.1% in the 4th quarter. Renaissance Technologies LLC now owns 318,400 shares of the medical instruments supplier’s stock valued at $4,935,000 after buying an additional 48,900 shares during the last quarter. Alliancebernstein L.P. increased its stake in STAAR Surgical by 9.4% in the 4th quarter. Alliancebernstein L.P. now owns 59,400 shares of the medical instruments supplier’s stock valued at $921,000 after buying an additional 5,100 shares during the last quarter. Geode Capital Management LLC increased its stake in STAAR Surgical by 4.8% in the 4th quarter. Geode Capital Management LLC now owns 274,602 shares of the medical instruments supplier’s stock valued at $4,255,000 after buying an additional 12,550 shares during the last quarter. King Luther Capital Management Corp acquired a new stake in STAAR Surgical in the 4th quarter valued at $319,000. Finally, Barrow Hanley Mewhinney & Strauss LLC acquired a new stake in STAAR Surgical in the 4th quarter valued at $1,150,000. Hedge funds and other institutional investors own 77.97% of the company’s stock.

Shares of STAAR Surgical (NASDAQ STAA) opened at $15.20 on Wednesday. The company has a market cap of $631.87, a price-to-earnings ratio of -380.00 and a beta of 1.25. STAAR Surgical has a 52-week low of $8.95 and a 52-week high of $17.60. The company has a debt-to-equity ratio of 0.02, a current ratio of 2.24 and a quick ratio of 1.72.

COPYRIGHT VIOLATION NOTICE: “$0.03 EPS Expected for STAAR Surgical (STAA) This Quarter” was reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this story on another website, it was illegally copied and republished in violation of US & international copyright & trademark laws. The legal version of this story can be accessed at https://theolympiareport.com/2018/02/14/0-03-eps-expected-for-staar-surgical-staa-this-quarter.html.

STAAR Surgical Company Profile

STAAR Surgical Company designs, develops, manufactures and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. It operates in the ophthalmic surgical market segment. Its principal products are intraocular lenses used in cataract surgery and implantable collamer lenses used in refractive surgery.

Get a free copy of the Zacks research report on STAAR Surgical (STAA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for STAAR Surgical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STAAR Surgical and related companies with MarketBeat.com's FREE daily email newsletter.